Paraoxonase-1 activity as a marker of atherosclerosis is not associated with low bone mineral density in healthy postmenopausal women

[1]  H. Çelik,et al.  Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. , 2007, Atherosclerosis.

[2]  A. Işık,et al.  Paraoxonase and arylesterase levels in rheumatoid arthritis , 2007, Clinical Rheumatology.

[3]  A. Sarandol,et al.  Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[4]  E. Barengolts,et al.  Coronary Calcification and Osteoporosis in Men and Postmenopausal Women Are Independent Processes Associated with Aging , 2006, Calcified Tissue International.

[5]  J. Magnus,et al.  Relationship between bone mineral density and myocardial infarction in US adults , 2005, Osteoporosis International.

[6]  A. LaCroix,et al.  Lack of a relation between vitamin and mineral antioxidants and bone mineral density: results from the Women's Health Initiative. , 2005, The American journal of clinical nutrition.

[7]  M. Aviram,et al.  Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. , 2004, Free radical biology & medicine.

[8]  J. Keaney,et al.  Role of oxidative modifications in atherosclerosis. , 2004, Physiological reviews.

[9]  J. Sayre,et al.  Aortic calcification and the risk of osteoporosis and fractures. , 2004, The Journal of clinical endocrinology and metabolism.

[10]  P. Pennisi,et al.  Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. , 2004, Osteoporosis International.

[11]  D. Kiel,et al.  Metacarpal cortical area and risk of coronary heart disease: the Framingham Study. , 2004, American journal of epidemiology.

[12]  G. Wesolowski,et al.  Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins , 2004, Cell Death and Differentiation.

[13]  D. Kiel,et al.  Long-term effects of serum cholesterol on bone mineral density in women and men: the Framingham Osteoporosis Study. , 2004, Bone.

[14]  C. Christiansen,et al.  Associated response in bone and lipids during hormone replacement therapy. , 2004, Maturitas.

[15]  N. Leitinger.  Cholesteryl ester oxidation products in atherosclerosis. , 2003, Molecular aspects of medicine.

[16]  P. McElduff,et al.  Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study , 2003, Circulation.

[17]  A. Yamashina,et al.  Increased pulse wave velocity associated with reduced calcaneal quantitative osteo-sono index: possible relationship between atherosclerosis and osteopenia. , 2003, The Journal of clinical endocrinology and metabolism.

[18]  C. Christiansen,et al.  Low Bone Mineral Density in the Hip as a Marker of Advanced Atherosclerosis in Elderly Women , 2003, Calcified Tissue International.

[19]  M. Catani,et al.  Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. , 2003, The Journal of clinical endocrinology and metabolism.

[20]  D. Shih,et al.  Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. , 2003, Free radical biology & medicine.

[21]  D. Shih,et al.  Human Serum Paraoxonase 1 Decreases Macrophage Cholesterol Biosynthesis: Possible Role for Its Phospholipase-A2-Like Activity and Lysophosphatidylcholine Formation , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[22]  E. Barrett-Connor,et al.  Retinol Intake and Bone Mineral Density in the Elderly: The Rancho Bernardo Study , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  John J. B. Anderson.  Oversupplementation of Vitamin A and Osteoporotic Fractures in the Elderly: To Supplement or Not to Supplement With Vitamin A , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  A. Hofman,et al.  Bone Mineral Density and the Risk of Peripheral Arterial Disease: The Rotterdam Study , 2002, Calcified Tissue International.

[25]  G. Davies,et al.  Elevated plasma lipid peroxide levels in angina pectoris and myocardial infarction. , 2002, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[26]  M. Aviram,et al.  Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. , 2002, Atherosclerosis.

[27]  E. Rubin,et al.  Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. , 2002, Biochemical and biophysical research communications.

[28]  A. Emili,et al.  Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. , 2002, Biochemical and biophysical research communications.

[29]  K. Michaëlsson,et al.  Association between oxidative stress and bone mineral density. , 2001, Biochemical and biophysical research communications.

[30]  A. Emili,et al.  Apolipoprotein A-I Promotes the Formation of Phosphatidylcholine Core Aldehydes That Are Hydrolyzed by Paraoxonase (PON-1) during High Density Lipoprotein Oxidation with a Peroxynitrite Donor* , 2001, The Journal of Biological Chemistry.

[31]  J. Orloff,et al.  Low Bone Density is Not Associated with Aortic Calcification , 2001, Calcified Tissue International.

[32]  D. Kiel,et al.  Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham heart study , 2001, Calcified Tissue International.

[33]  Y. Takeuchi,et al.  Effects of 1-year treatment with fluvastatin or pravastatin on bone. , 2001, The American journal of medicine.

[34]  C. Cooper,et al.  Use of statins and risk of fractures. , 2001, JAMA.

[35]  P. Durrington,et al.  Paraoxonase and Atherosclerosis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[36]  I. Reid,et al.  Effect of pravastatin on frequency of fracture in the LIPID study: secondly analysis of a randomised controlled trial , 2001, The Lancet.

[37]  F. Parhami,et al.  Atherogenic High‐Fat Diet Reduces Bone Mineralization in Mice , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  G. Schellenberg,et al.  Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[39]  A. Hofman,et al.  Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[40]  D. Shih,et al.  Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis* , 2000, The Journal of Biological Chemistry.

[41]  M. Aviram,et al.  Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. , 2000, Circulation.

[42]  A. Boulton,et al.  Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. , 2000, Clinical science.

[43]  Y. Chung,et al.  HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. , 2000, The Journal of clinical endocrinology and metabolism.

[44]  C. Hassager,et al.  The association between low bone mass at the menopause and cardiovascular mortality. , 1999, The American journal of medicine.

[45]  Jeetesh V. Patel,et al.  Serum paraoxonase after myocardial infarction. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[46]  B. La Du,et al.  Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[47]  G. Greendale,et al.  The Relation of Dietary Vitamin C Intake to Bone Mineral Density: Results from the PEPI Study , 1998, Calcified Tissue International.

[48]  A. Girotti.  Lipid hydroperoxide generation, turnover, and effector action in biological systems. , 1998, Journal of lipid research.

[49]  B. La Du,et al.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. , 1998, The Journal of clinical investigation.

[50]  E. Barengolts,et al.  Osteoporosis and Coronary Atherosclerosis in Asymptomatic Postmenopausal Women , 1998, Calcified Tissue International.

[51]  T. Osawa,et al.  [Oxidative stress and atherosclerosis]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[52]  Y. Ouchi,et al.  Association of Bone Mineral Density with Apolipoprotein E Phenotype , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[53]  J. Cauley,et al.  Bone Mineral Density and Aortic Calcification: The Study of Osteoporotic Fractures , 1997, Journal of the American Geriatrics Society.

[54]  P. Edwards,et al.  The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[55]  J. Berliner,et al.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[56]  J. Berliner,et al.  Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[57]  I. Reid,et al.  Determinants of the rate of bone loss in normal postmenopausal women. , 1994, The Journal of clinical endocrinology and metabolism.

[58]  C. Abbott,et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.

[59]  M. Frye,et al.  Osteoporosis and calcification of the aorta. , 1992, Bone and mineral.

[60]  I. Kovács,et al.  Simple and specific test for measuring lipid peroxides in plasma. , 1991, Journal of clinical pathology.

[61]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[62]  C. Walker,et al.  Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. , 1986, Clinical chemistry.

[63]  J. Kelsey,et al.  Associations of vitamin C, calcium and protein with bone mass in postmenopausal Mexican American women , 2007, Osteoporosis International.

[64]  S. B. Nielsen,et al.  Does serum cholesterol contribute to vertebral bone loss in postmenopausal women? , 2003, Bone.

[65]  M. Aviram,et al.  Oxysterol-induced activation of macrophage NADPH-oxidase enhances cell-mediated oxidation of LDL in the atherosclerotic apolipoprotein E deficient mouse: inhibitory role for vitamin E. , 2002, Atherosclerosis.

[66]  I. Reid,et al.  Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. , 2001, Lancet.